Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis

International Journal of Tissue Reactions

Volumn 24, Issue 3, 2002, Pages 111-115

  Malyszko, Jolanta ^a   Malyszko, J S ^a   Hryszko, T ^a   Brzosko, S ^a   Mysliwiec, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; CELL ADHESION MOLECULE; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTRACELLULAR CELL ADHESION MOLECULE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; SIMVASTATIN; THROMBOMODULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INTRACELLULAR SPACE; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; OUTCOMES RESEARCH; SIDE EFFECT; THROMBOSIS; TREATMENT PLANNING;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; SIMVASTATIN; THROMBOMODULIN; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036919332     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The Lipid Research Clinic Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365, 1984.
2. The Scandinavian Simvastatin Study Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
3. Vogel R.A., Corretti M.C., Plotnick G.D. Changes in flow mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am. J. Cardiol., 77, 37, 1996.
4. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 1126, 1997.
5. Ross R. Atherosclerosis - An inflammatory disease. N. Engl. J. Med., 340, 115, 1999.
6. Weber C., Erl W., Weber K.S.C., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol., 30, 1212, 1997.
7. Ocatelli F., Del Vecchio L., Manzoni C. Morbidity and mortality in maintenance hemodialysis. Nephron, 80, 380, 1998.
8. Malyszko J., Malyszko J.S., Hryszko T., Mysliwiec M. Simvastatin affects TAFI and thrombomodulin in CAPD patients. Thromb. Haemost., 86, 900, 2001.
9. Malyszko J., Malyszko J.S., Hryszko T., Mysliwiec M. Effects of long-term treatment with simvastatin on some hemostatic parameters in CAPD patients. Am. J. Nephrol., 21, 373, 2001.
10. La Rosa J.C. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol., 88, 291, 2001.
11. Blann A.D., Davis A., Miller J.P., McCollum C.N. Von Willebrand factor and soluble E selection in hyperlipidemia: Relationship to lipids and vascular disease. Am. J. Hematol., 55, 15, 1997.
12. Romano M., Mezzetti A., Maruli C., et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients. J. Invest. Med., 48, 183, 2000.
13. Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation, 104, 376, 2001.
14. Guijarro C., Keane W.F. Effects of lipids on the pathogenesis of progressive renal failure: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner. Electrolyte Metab., 22, 147, 1996.
15. Blann A.D., Gurney D., Hughes E., Buggins P., Silverman S.H., Lip G.Y.H. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am. J. Cardiol., 88, 89, 2001.
16. Kario K., Matsuo T., Hoshide S., et al. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Blood Coag. Fibrinol., 10, 269, 1999.
17. Asberg A., Hartmann A., Fjeldsa E., Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol. Dial. Transplant., 12, 1920, 2001.
18. Ambrosi P., Aillaud M.F., Habib G., et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb. Haemost., 83, 46, 2000.
19. Chang J.W., Yang W.S., Min W.K., Lee S.K., Park J.S., Kim S.B. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am. J. Kidney Dis., 39, 1213, 2002.